Rare Disease Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve patient ...

The adjusted mean change in forced vital capacity at week 52 was –107.1 mL in patients given placebo, –61.2 mL in patients treated with 9 mg of nerandomilast twice a day, and –64.9 mL in patients ...

Researchers developed an AI-based framework that can generate a report like a primary care physician, which can then help identify undiagnosed patients with ATTR-CM and individuals who are at risk of ...

The FDA granted Fast Track Designation to coramitug for ATTR-CM as it advances in the ongoing phase 3 CLEOPATTRA trial. The US Food and Drug Administration (FDA) has granted Fast Track Designation to ...

In the ADAPT SERON trial, treatment with efgartigimod led to rapid, significant, and sustained improvements in symptoms such as speech, vision, swallowing, and physical function. The US Food and Drug ...

There were 7 cases of PAH temporally associated with bevacizumab in the French Pulmonary Hypertension Registry, but most had predisposing conditions. Bevacizumab exposure does not seem to lead to the ...

Test Your Knowledge About the Signs and Symptoms of FNAIT Test Your Knowledge About the Epidemiology of FNAIT Test Your Knowledge About the Diagnosis of FNAIT Rare Disease Advisor, a trusted source of ...

The relative left ventricular wall thickness, indicating relative wall thickening, was significantly higher in patients who were technetium-99m pyrophosphate (99mTc-PYP) positive compared with ...

Nephrologist Gates Colbert, MD, speaks at the Renal Physicians Association 2026 Annual Meeting in Atlanta, Georgia (Photo by Riya Ajmera) With 4 pivotal therapy types now available, CKD remission is ...

Genetic analysis of 2 independent cohorts showed celiac disease increases the odds of pulmonary arterial hypertension, with a meta-analysis odds ratio of 1.136. Celiac disease increases the risk of ...

Investigators will enroll approximately 100 boys with early ambulatory stage DMD in a new 72-week randomized controlled trial. Delandistrogene moxeparvovec (Elevidys ™), the first approved gene ...